Compare GWRS & ANIK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GWRS | ANIK |
|---|---|---|
| Founded | 2003 | 1983 |
| Country | United States | United States |
| Employees | N/A | 235 |
| Industry | Water Supply | Medical/Dental Instruments |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 214.3M | 197.6M |
| IPO Year | 2008 | 1996 |
| Metric | GWRS | ANIK |
|---|---|---|
| Price | $7.06 | $14.58 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 1 |
| Target Price | $9.20 | ★ $17.00 |
| AVG Volume (30 Days) | 51.5K | ★ 116.4K |
| Earning Date | 05-13-2026 | 04-29-2026 |
| Dividend Yield | ★ 4.22% | N/A |
| EPS Growth | N/A | ★ 80.16 |
| EPS | ★ 0.11 | N/A |
| Revenue | $41,914,000.00 | ★ $112,819,000.00 |
| Revenue This Year | $15.29 | $5.98 |
| Revenue Next Year | $8.28 | $7.42 |
| P/E Ratio | $64.55 | ★ N/A |
| Revenue Growth | ★ 8.51 | N/A |
| 52 Week Low | $7.07 | $7.90 |
| 52 Week High | $11.17 | $16.24 |
| Indicator | GWRS | ANIK |
|---|---|---|
| Relative Strength Index (RSI) | 32.09 | 49.53 |
| Support Level | N/A | $13.81 |
| Resistance Level | $7.82 | $15.01 |
| Average True Range (ATR) | 0.17 | 0.92 |
| MACD | -0.03 | -0.23 |
| Stochastic Oscillator | 1.92 | 60.19 |
Global Water Resources Inc operates as a water resources management company that owns, operates, and manages water, wastewater, and recycled water utilities in strategically located communities, principally in metropolitan Phoenix and Tucson, Arizona. It operates within the State of Arizona. Operating revenue of the company is derived from regulated water, wastewater, and recycled water service provided to customers based upon tariff rates.
Anika Therapeutics Inc operates in the OA Pain Management and regenerative solutions space, focusing on early intervention orthopedics. The company leverages proprietary hyaluronic acid (HA) technology to develop differentiated products and provides products and services. Its OA Pain Management products include Orthovisc, Monovisc, and Cingal. Monovisc and Orthovisc are single- and multi-injection HA viscosupplement products indicated for pain relief from OA conditions and are generally administered to patients in an office setting. In the United States, Monovisc and Orthovisc are marketed exclusively by Johnson & Johnson MedTech. It generates maximum revenue from the OEM Channel and derives the majority of its revenue from the United States, with a presence in Europe and other countries.